HANSOH PHARMA(HK:03692) Cai Jing Wang·2025-10-17 20:31Core Viewpoint - Hansoh Pharmaceutical Group Limited has signed a licensing agreement with Roche for HS-20110, a targeted antibody-drug conjugate (ADC) utilizing a clinically validated topoisomerase inhibitor, granting Roche exclusive rights for development and commercialization outside of Greater China [1] Group 1: Licensing Agreement Details - The agreement includes an upfront payment of $80 million and potential milestone payments based on development, regulatory approval, and commercialization progress, with a total deal value of up to $1.45 billion [1] - HS-20110 is a novel potential first-in-class ADC, combining a humanized monoclonal antibody targeting cadherin-17 (CDH17) with a topoisomerase inhibitor payload [1] Group 2: Clinical Development - The therapy shows broad application potential in solid tumors and is currently undergoing global Phase I clinical trials for the treatment of colorectal cancer and other solid tumors in China and the United States [1]